RHEUMATOID ARTHRITIS: DIAGNOSIS, TREATMENT


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper gives data on the pathogenesis of rheumatoid arthritis, new diagnostic (ACR/EULAR) criteria for the disease and its treatment, including the role of nonsteroidal anti-inflammatory drugs and corticosteroids, disease-modifying antirheumatic drugs, and a new class of genetically engineered agents.

全文:

受限制的访问

作者简介

R. Balabanova

Research Institute of Rheumatology, Russian Academy of Medical Sciences

Email: nauka@irramn.ru
Professor, MD

参考

  1. Turesson C., McClelland R., Christianson T. et al. Multiple extra-articular manifestations are associated with poor survival in patients with rheumatoid arthritis // Ann. Rheum. Dis. - 2006; 65: 1533-4.
  2. Pincus T. Long term outcomes in rheumatoid arthritis // Br. J. Rheum. -1995; 34 (2): 59-73.
  3. Arnett F., Edworthy S., Dougados M. et al. The ACR 1987 revised criteria for the classification of rheumatoid arthritis // Arthr. Rheum. - 1988; 31: 315-24.
  4. Emery P., Breedveld F., Dougados M. et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide // Ann. Rheum. Dis. - 2002; 61: 290-7.
  5. Aletaha D., Neogi T., Silman A. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology / European League Against Rheumatism collaborative initiative // Ann. Rheum. Dis. - 2010; 69: 1580-8.
  6. Сальникова Т.С. Сравнительная оценка эффективности делагила,сульфасалазина и метотрексата на ранней стадии ревматоидного артрита. Автореф. дисс. ... канд. мед. наук - 2003; с. 8-9.
  7. Каратеев А.Е. НПВП-гастропатии:динамика за 12 лет // Научнопрактическая ревматология. - 2011; 3: 20-4.
  8. Van der Goes, Jacobs J., Boers M. et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice // Ann. Rheum. Dis. - 2010; 69: 1913-9.
  9. Насонов Е.Л. Метотрексат. Перспективы применения в ревматологии. -М., 2005; с. 196.
  10. Braun J., Kastner P., Flaxenberg P. et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis // Arthr. Rheum. - 2008; 1: 73-81.
  11. Балабанова Р.М., Кашеваров Р.Ю., Олюнин Ю.А. и соавт. Антидеструктивное действие лефлуномида при раннем ревматоидном артрите // Тер. архив. - 2006; 20: 6-10.
  12. Чичасова Н.В., Имаметдинова Г.Р., Насонов Е.Л. Место плаквенила в современной терапии ревматоидного артрита // РМЖ. - 2009; 7: 487-90.
  13. Iking-Kornet Ch., Aringer M., Wollenhaupt J. et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase 111 b study TAMARA as an example and their comparison with traditional remission criteria // Ann. Rheum. Dis. - 2011; 70: 1986-90.
  14. Furst D., Keystone E., Braun J. et al. Update consensus statement on biological agents for treatment of rheumatic diseases, 2010 // Ann. Rheum. Dis. -2011; 70: 2-36.

补充文件

附件文件
动作
1. JATS XML
##common.cookie##